Last updated: September 1, 2026
Chlorothiazide sodium is a mature, off-patent thiazide diuretic used primarily as an injectable hospital product. Its commercial value is concentrated in low-volume institutional demand, pediatric and critical-care use, and treatment of fluid overload when oral therapy is impractical. The product has no meaningful remaining patent exclusivity, no biosimilar pathway, and limited public revenue disclosure. Financial performance depends more on sterile-manufacturing capacity, hospital contracting, shortages, and generic competition than on clinical differentiation.
What is chlorothiazide sodium and how is it used?
Chlorothiazide sodium is the injectable sodium salt of chlorothiazide. It is administered intravenously or, in some labeling, intramuscularly when rapid or parenteral diuresis is required. The drug inhibits sodium and chloride reabsorption in the distal renal tubule, increasing urinary excretion of sodium, chloride, and water.
The product is used for:
- Edema associated with congestive heart failure, hepatic cirrhosis, corticosteroid therapy, and estrogen therapy
- Hypertension, usually as an adjunct rather than first-line monotherapy
- Hospitalized patients who cannot take oral diuretics
- Pediatric fluid management and neonatal or pediatric intensive-care use
- Diuretic resistance, often in combination with a loop diuretic
The injectable product is generally marketed as chlorothiazide sodium for injection, while oral products contain chlorothiazide as tablets or suspension. The injectable sodium salt should be analyzed as a distinct commercial segment because its manufacturing, procurement, and shortage risks differ from those of oral chlorothiazide.
What is the FDA regulatory status of chlorothiazide sodium?
Chlorothiazide sodium is an FDA-approved prescription drug. The reference product is associated with the Diuril brand, historically marketed in oral and injectable forms. Generic products may be approved through abbreviated new drug applications under the FDA’s generic-drug pathway.
| Regulatory characteristic |
Chlorothiazide sodium |
| FDA pathway |
Original NDA and subsequent ANDA products |
| Drug class |
Thiazide diuretic |
| Administration |
Injectable; oral chlorothiazide products are separate dosage forms |
| Prescription status |
Prescription-only |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Reference brand |
Diuril and related chlorothiazide products |
| Therapeutic areas |
Edema, hypertension, inpatient diuresis |
| FDA exclusivity today |
No meaningful remaining new-drug exclusivity expected |
| Patent position |
Mature, off-patent small molecule |
The FDA label identifies adverse effects including electrolyte depletion, hypokalemia, hyponatremia, hyperglycemia, hyperuricemia, renal impairment, and hypersensitivity reactions. These risks require electrolyte and renal monitoring, particularly in hospitalized patients receiving combination diuretic therapy (FDA, n.d.-a).
What patents protect chlorothiazide sodium?
No commercially significant active patent estate is generally associated with chlorothiazide sodium. The compound was introduced more than six decades ago, and any original compound, composition, and basic-use patents expired long ago.
Orange Book status
Current Orange Book analysis should focus on whether an individual listed product has active patent entries or regulatory exclusivity. For mature chlorothiazide products, the commercial risk profile is consistent with an off-patent product:
| IP category |
Commercial assessment |
| Compound patent |
Expired |
| Basic formulation patent |
Expired or commercially irrelevant |
| Method-of-use patent |
No material exclusivity expected |
| Pediatric exclusivity |
No current product-level exclusivity expected |
| NCE exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| Patent litigation exposure |
Low |
| Paragraph IV exposure |
Low as a branded-product issue; generic substitution risk is high |
No known active patent position gives chlorothiazide sodium a durable barrier against generic competition. Any current patent listing would need to be assessed product by product in the FDA Orange Book because listings can differ between oral and injectable presentations (FDA, n.d.-b).
When did chlorothiazide sodium lose exclusivity?
Chlorothiazide lost meaningful exclusivity decades ago. The drug was introduced in the late 1950s, making its original regulatory and patent exclusivity periods long expired. The commercial market is therefore governed by generic entry rather than branded exclusivity.
The relevant timeline is:
| Period |
Event |
| 1950s |
Chlorothiazide introduced as an early thiazide diuretic |
| 1960s-1980s |
Broad clinical adoption in hypertension and edema |
| Later decades |
Generic oral and injectable competition developed |
| Current market |
Mature generic market with limited brand premium |
The absence of meaningful exclusivity does not eliminate supply barriers. Injectable products remain more difficult to manufacture than tablets because they require validated sterile processing, container-closure controls, assay and particulate testing, and reliable supply of active pharmaceutical ingredient and packaging components.
How large is the chlorothiazide sodium market?
Public company filings generally do not report chlorothiazide sodium revenue as a separate line item. The product is usually included within broader generic pharmaceuticals, hospital products, or legacy branded portfolios. As a result, a defensible product-specific global market-size estimate cannot be derived from public filings alone.
The market is best characterized as:
- Low revenue per treatment course
- Low annual growth
- High generic substitution
- Low brand loyalty in routine oral therapy
- Greater commercial relevance in hospitals for the injectable formulation
- Demand driven by clinical need rather than consumer marketing
- Vulnerability to supply interruptions because the market has limited suppliers
The injectable segment can command a higher unit price than oral chlorothiazide because sterile manufacturing is more expensive and hospital buyers value availability. That pricing advantage does not necessarily translate into high profitability. Contracting pressure, wholesaler fees, inventory requirements, and manufacturing compliance costs can absorb much of the gross margin.
What drives demand for chlorothiazide sodium?
Demand is linked to hospital utilization, heart-failure admissions, pediatric intensive care, renal disease, and the use of sequential nephron blockade.
Heart-failure and inpatient demand
Loop diuretics such as furosemide remain the mainstay of acute congestion management. Chlorothiazide may be added when loop-diuretic response is inadequate. The 2022 AHA/ACC/HFSA heart-failure guideline recognizes the use of thiazide-type diuretics with loop diuretics for patients who do not respond adequately to moderate- or high-dose loop therapy (Heidenreich et al., 2022).
Pediatric and neonatal demand
The injectable product has a specialized role in pediatric and neonatal care, where oral administration may be difficult and precise fluid management is required. This segment is small in volume but commercially important because hospitals may maintain inventory even when routine adult demand is limited.
Hypertension
Thiazide-type therapy remains an established hypertension treatment class. However, chlorothiazide competes with hydrochlorothiazide, chlorthalidone, and indapamide. Chlorthalidone has a longer duration of action, while hydrochlorothiazide is more widely available and familiar to prescribers (Whelton et al., 2018).
How does chlorothiazide sodium compare with competing diuretics?
| Product |
Primary competitive advantage |
Limitation versus chlorothiazide sodium |
| Furosemide injection |
Rapid, potent loop diuresis; broad hospital use |
Greater electrolyte and volume-depletion risk; not a thiazide substitute |
| Bumetanide injection |
High potency and small administration volume |
Higher cost in some settings; smaller market |
| Hydrochlorothiazide |
Low cost, broad generic availability, extensive hypertension use |
Oral-only routine use; less useful when oral dosing is not possible |
| Chlorthalidone |
Longer half-life and strong hypertension positioning |
Oral-only; prolonged electrolyte effects |
| Metolazone |
Useful sequential nephron blockade and oral administration |
Less convenient for patients unable to take oral drugs |
| Chlorothiazide sodium injection |
Parenteral thiazide option for hospital diuresis |
Low routine outpatient use and limited supplier base |
Chlorothiazide sodium is most differentiated by route of administration, not by molecular novelty. Its key substitute in acute care is often not another thiazide but an injectable loop diuretic.
What formulation patents protect chlorothiazide sodium?
No major active formulation-patent strategy is associated with standard chlorothiazide sodium injection. Commercial differentiation rests on manufacturing execution, vial configuration, concentration, preservative profile, stability, storage requirements, and distribution reliability.
Potential technical barriers include:
- Sterile compounding and aseptic filling
- Control of particulate matter and endotoxins
- Stability of the sodium salt in solution
- Container-closure integrity
- Batch-release testing
- Availability of suitable injectable-grade API
- Validation of sterilization and cleaning processes
- Hospital compatibility and administration instructions
These are regulatory and operational barriers rather than patent barriers. A new entrant would normally need an ANDA supported by pharmaceutical equivalence, bioequivalence or appropriate parenteral-product requirements, chemistry and manufacturing controls, and facility compliance.
Which companies compete in chlorothiazide sodium?
The market includes the Diuril reference brand and generic manufacturers supplying oral and injectable products. Product ownership and manufacturing arrangements can change through licensing, divestitures, contract manufacturing, and portfolio transfers.
The relevant competitive groups are:
- The reference-brand rights holder or marketer.
- Generic injectable manufacturers with FDA-approved sterile facilities.
- Generic oral manufacturers supplying tablets or suspension.
- Hospital-focused suppliers and wholesalers.
- Contract manufacturers that produce sterile vials for marketing authorization holders.
The most important competitive variable is not the number of theoretical ANDA holders. It is the number of manufacturers actively producing and reliably distributing the injectable product. A product may have several approved suppliers while only one or two remain commercially active.
What patent litigation and Paragraph IV risks exist?
Chlorothiazide sodium has low current Paragraph IV litigation risk because the original drug and conventional formulations are long off-patent. Paragraph IV certifications are most relevant when an ANDA applicant challenges a listed patent. For a mature chlorothiazide product with no material active Orange Book patents, the more likely regulatory outcome is a standard generic approval without branded patent litigation.
Litigation exposure could arise from:
- A newly listed formulation or device patent
- A manufacturing-process dispute outside the Orange Book
- Trade-secret claims involving sterile production
- Contract or supply disputes
- State-law commercial disputes over shortage allocation or distribution
These risks are distinct from the patent-driven litigation commonly associated with recently approved branded drugs.
What is the financial trajectory for chlorothiazide sodium?
The financial trajectory is mature to declining in routine outpatient use, with a more stable niche in hospital injectable demand.
| Financial driver |
Expected effect |
| Generic substitution |
Sustained price pressure |
| Low clinical novelty |
Limits premium pricing |
| Hospital demand |
Provides recurring but narrow volume |
| Sterile-manufacturing scarcity |
Can support temporary price increases |
| Supply shortages |
Can raise revenue but increase regulatory and operational risk |
| Oral competition |
Limits expansion in hypertension |
| Pediatric and critical-care use |
Supports specialized demand |
| Product bundling |
May improve portfolio economics for generic suppliers |
| Brand marketing |
Limited return on investment |
| Patent expiry |
No remaining exclusivity premium |
Revenue can rise temporarily during a shortage or following a competitor exit. That increase is not equivalent to durable market growth. If additional sterile suppliers enter, prices generally move toward generic-market levels.
For a portfolio company, chlorothiazide sodium is more valuable as part of a hospital injectable franchise than as a standalone growth asset. Shared manufacturing, sales, distribution, and regulatory infrastructure can improve economics. A standalone commercial operation would face limited revenue scale and high compliance costs.
What generic launch scenarios exist for chlorothiazide sodium?
Base case: stable generic supply
Multiple active suppliers maintain routine availability. Prices remain low, hospitals use the product selectively, and revenue remains broadly flat or declines gradually.
Upside case: competitor exit or shortage
A sterile manufacturer discontinues the product, experiences a quality problem, or reallocates capacity. Remaining suppliers gain volume and may obtain higher net pricing. FDA shortage reporting becomes a key market signal (FDA, n.d.-c).
Downside case: substitution and formulary compression
Hospitals substitute furosemide, bumetanide, metolazone, or another thiazide-type product. Injectable chlorothiazide volume declines, particularly if procurement teams standardize around a smaller number of diuretics.
Entry case: new ANDA supplier
A new manufacturer enters with an approved sterile product. The entrant can capture share if it offers reliable supply, competitive pricing, and wholesaler access. Patent clearance is unlikely to be the principal entry obstacle.
How strong is the chlorothiazide sodium patent estate?
The patent estate is weak from a defensive and investment perspective. There is no evident remaining compound exclusivity, no meaningful Orange Book patent moat, and no biosimilar complexity. The durable barriers are operational:
- FDA-compliant sterile manufacturing
- Reliable API sourcing
- Hospital contracting
- Distribution access
- Shortage-response capability
- Quality-system performance
This profile favors established generic companies with injectable infrastructure. It is less attractive for a company seeking a patent-protected lifecycle-management asset.
Key Takeaways
- Chlorothiazide sodium is a mature, off-patent injectable thiazide diuretic.
- Its main commercial niche is hospital use, including pediatric care, parenteral diuresis, and sequential nephron blockade.
- There is no meaningful remaining NCE, compound, or formulation exclusivity.
- Patent litigation and Paragraph IV risk are low relative to newer branded pharmaceuticals.
- The main market barrier is sterile manufacturing and dependable supply, not intellectual property.
- Routine oral demand faces competition from hydrochlorothiazide, chlorthalidone, indapamide, and metolazone.
- Product-specific revenue is generally not disclosed by manufacturers.
- Financial performance is likely stable to declining in normal conditions, with temporary upside during shortages or supplier exits.
- The asset has greater value within a hospital-injectable portfolio than as a standalone branded product.
- Biosimilar risk is irrelevant because chlorothiazide sodium is a small-molecule drug.
FAQs
Is chlorothiazide sodium the same as hydrochlorothiazide?
No. Both are thiazide diuretics, but they are different active ingredients. Chlorothiazide sodium is commonly associated with the injectable product, while hydrochlorothiazide is predominantly used orally.
Can chlorothiazide sodium be substituted for furosemide?
Not on a simple milligram-for-milligram basis. The drugs have different mechanisms, potency, pharmacokinetics, and clinical roles. Hospital substitution requires prescriber-directed dosing and monitoring.
Does chlorothiazide sodium have an active composition-of-matter patent?
No commercially meaningful composition-of-matter exclusivity remains. The drug has been marketed since the 1950s.
Is chlorothiazide sodium listed as a current FDA drug shortage?
Shortage status can change by product, manufacturer, presentation, and date. The FDA Drug Shortages database is the controlling source for current availability status.
Is chlorothiazide sodium attractive for pharmaceutical licensing?
It is generally a low-value standalone licensing asset. Its commercial attractiveness improves when combined with an established sterile-injectable portfolio, hospital distribution network, or manufacturing platform.
References
-
Food and Drug Administration. (n.d.-a). Diuril (chlorothiazide sodium) injection prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.-c). Drug shortages database. U.S. Department of Health and Human Services.
-
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedewa, A. Y., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
